Hiroaki Suga

Source: Wikipedia, the free encyclopedia.
Hiroaki Suga
Born
菅 裕明

(1963-02-21) February 21, 1963 (age 61)
PhD)
Known forRNA-based catalysis
Awards
Scientific career
FieldsChemistry
Institutions
ThesisCatalytic antibodies elicited via homologous and heterologous immunization (1994)
Doctoral advisorSatoru Masamune [jp]

Hiroaki Suga (菅 裕明, born February 21, 1963) is a Japanese biochemist and businessman. He is best known for his work on artificial

ribozymes (flexizymes) and their application in mRNA display (RaPID, random nonstandard peptide integrated discovery).[1][2]

Suga was awarded the 2023

proteins and for creating strategies to harness the capabilities of these biopolymers in new ways to ameliorate human diseases."[1]

Education

Suga graduated from Okayama University (BSc, MSc) in engineering,[1][3] and studied at University of Lausanne, where he worked with Manfred Schlosser [de].[3]

Suga completed his Ph.D. in chemistry at

antibodies[4]

Career

Scientific

After graduating from

postdoctoral researcher at the Jack W. Szostak lab of Harvard Medical School before starting his independent career at University at Buffalo. Since 2003 he is a faculty member at the University of Tokyo.[3]

Business

Suga is also a founder of PeptiDream Inc. Tokyo, a publicly traded biopharmaceutical start-up company responsible for discovering and developing non-standard peptide therapeutics in addition to addressing unmet medical needs as well as investigating peptide drug conjugates (PDC), peptides, and small molecule-based drugs.[5][6][7] It is traded publicly on the Tokyo First Stock Exchange Market (the market capitalization is over JY 600 billions), which has many partnerships with pharmaceutical companies in worldwide.[2][8]

Suga is chair of the editorial board at RSC Chemical Biology[9] and associate editor at Angewandte Chemie.[2]

Publications

Suga has published over 250 scientific articles;[10] a small selection is presented here:

  • Lee, Nick; Bessho, Yoshitaka; Wei, Kenneth; Szostak, Jack W.; Suga, Hiroaki (2000). "Ribozyme-catalyzed tRNA aminoacylation". Nature Structural Biology. 7 (1): 28–33.
    S2CID 1831912
    .
  • Ramaswamy, Krishna; Saito, Hirohide; Murakami, Hiroshi; Shiba, Kiyotaka; Suga, Hiroaki (2004). "Designer Ribozymes: Programming the tRNA Specificity into Flexizyme". Journal of the American Chemical Society. 126 (37): 11454–11455.
    PMID 15366888
    .
  • Passioura, Toby; Suga, Hiroaki (2017). "A RaPID way to discover nonstandard macrocyclic peptide modulators of drug targets". Chemical Communications. 53 (12): 1931–1940.
    PMID 28091672
    .

Awards

References

  1. ^ a b c d "Press release: Wolf Prize in Chemistry 2023" (Press release). Wolf Foundation. February 7, 2023.
  2. ^ a b c d e f "Press release: 2023 Wolf Prize in Chemistry Announced" (Press release). Chemistry Views. February 7, 2023.
  3. ^ a b c d "Hiroaki Suga, Ph.D. | Biographical Information". Retrieved February 11, 2023.
  4. hdl:1721.1/17342
    .
  5. ^ "Prof. Dr. Hiroaki Suga: The pseudo-natural peptides therapeutic innovation". LMU München. December 10, 2018.
  6. ^ "Hiroaki Suga".
  7. ^ "Current Lecturer". November 11, 2022.
  8. ^ "Hiroaki Suga, Professor, University of Tokyo". Swiss National Center of Competence in Research. March 14, 2016.
  9. ^ "RSC Chemical Biology | About". Retrieved February 11, 2023.
  10. ^ "Suga Lab | Articles & Reviews". Retrieved February 11, 2023.
  11. ^ a b "Press release: UTokyo Professor Hiroaki Suga wins 2023 Wolf Prize in chemistry" (Press release). University of Tokyo. February 13, 2023.
  12. ^ "American Peptide Society | Vincent du Vigneaud Award". Retrieved February 11, 2023.
  13. ^ "Congratulations to Hiroaki Suga, awarded the Humboldt Research Award". Retrieved February 18, 2023.

External links

Scholia has a profile for Hiroaki Suga (Q11619370).
Retrieved from "https://en.wikipedia.org/w/index.php?title=Hiroaki_Suga&oldid=1177205327"